Worldwide Database on Diabetes Care Intelligence - Featuring Acon, Arkray and Dexcom Among Others
Dublin, Dec. 07, 2021 (GLOBE NEWSWIRE) -- The "Diabetes Care Intelligence Center" report has been added to ResearchAndMarkets.com's offering.
This reportis a global intelligence database on diabetes drugs & devices, which offers data on 25 major countries. It covers 13 years of comparable data, including 5-year forecasts incorporating value, volume sales, and price and price per-capita expenditure.
The Intelligence Centre enhances your understanding of the diabetes drugs industry, along with economic factors impacting diabetes drug usage, such as diabetes population, Type 1 and Type 2 Diabetic population, and obesity, which provide you with actionable business insights.
Market Scope
Diabetes drugs & devices market data, volume and value analytics with growth trends (2012-2023)
Branded & generic drugs and devices' sales data from 2012-2023
Segment, sub-segment & company devices' sales data from 2012-2023
Additional information includes - diabetic population levels, diabetes prevalence, Diabetes Type 1 population, Diabetes Type 2 population, and per-capita expenditure.
It exhaustive coverage (countries covered account for more than 80% of the overall spending on diabetes). Covering and tracking of over 18,000 data points of the diabetes drugs industry, which covers various categories, segments, Active Pharmaceutical Ingredients (APIs), and brands. It also covers more than 8,000 data points of the diabetes care device market, which encompass various categories, segments, sub-segments and company share analysis.
Diabetes Drug Categories:
Insulin
Basal Insulin or Long-acting Insulin
Bolus Insulin or Fast-acting Insulin
Pre-mixed Insulin or Combination Insulin
Traditional Human Insulins
Traditional Human Insulin Biosimilars
Insulin Glargine Biosimilars
Non-Insulin Injectable
GLP-1 Agonist Market
Amylin Analogue
Oral Anti-diabetics Drugs
Dopamine-D2 Receptor Agonist
Meglitinide
Alpha-Glucosidase Inhibitors
SGLT2 Inhibitors
Biguanides
Sulfonylureas
DPP-4 Inhibitors
Combination Drugs
Insulin Combinations
Oral Combinations
Diabetes Device Categories
Management Devices
Insulin-delivery Devices
Insulin Syringes
Cartridges in Reusable Pens
Disposable Pens
Jet Injectors
Insulin Pump
Insulin Pump Devices
Insulin Pump Reservoirs
Infusion Sets
Monitoring Devices
Self-monitoring Blood Glucose Devices (SMBG)
By Component:
Glucometer Devices
Test Strips
Lancets
By End-user
Hospital
Glucometer Devices
Test Strips
Lancets
Personal
Glucometer Devices
Test Strips
Lancets
Continuous Glucose Monitoring Devices (CGM)
CGM durables (Receivers and Transmitters)
Sensors
Companies Mentioned
Abbott Diabetes Care
Acon
Agamatrix Inc.
Arkray
Ascensia Diabetes Care
Astellas
AstraZeneca
Bionime Corporation
Boehringer Ingelheim
Bristol Myers Squibb
Dexcom
Eli Lilly
Janssen Pharmaceuticals
Johnson & Johnson
Medisana
Medtronic
Merck and Co.
Novartis
Novo Nordisk
Pfizer
Roche
Rossmax
Sanofi
Takeda
Trivida
Market Overview
The global diabetes care market is expected to grow because of the growing diabetes population levels and increasing diabetes expenditure in established, as well as pharm emerging countries.
Global Rise in Diabetic Population
There has been a tremendous increase in the global diabetic population levels over the past decade. Several reports and surveys documented a drastic increase in the diabetic population levels, based on the changing lifestyles and habits.
Extensive urbanization in various parts of the globe is considered to be the primary cause of obesity, health deterioration, physical inactivity, etc. Owing to these factors the prevalence of Type 2 Diabetes mellitus (T2DM) has increased significantly.
It is estimated that out of the total 415 million people suffering from diabetes worldwide, 46% of this demographic is those with undiagnosed diabetes.
The growing diabetic population levels act as a driver for insulin monitoring devices, such as glucometers, CGMs, etc. In developed countries, close to 90% of Type 1 Diabetic patients use glucometers. It is expected that during the forecast period close to 50% of Type 2 Diabetic patients will use a glucometer.
The United States Leads the Diabetes Drugs & Devices Market
In 2017, the US diabetes drugs market held the largest market share in North America, due to the presence of a high-quality healthcare system and increasing prevalence of diabetes in the region.
In the Asia-Pacific region, China and India have been identified as potential emerging markets, due to the rising diabetic population levels.
Reasons to Purchase this Dashboard
More Granular: Covers more categories, segments and brands' information at country- and global-levels compared to other market intelligence providers
Analyzing the outlook of the market with recent market data, historical data and market forecast
Ease of Comparability: Analytics are based on a standardized definition across the globe to facilitate better comparability of market data
View the market in different ways among categories and geography to understand where actual opportunities lie
Market segmentation including quantitative research, incorporating the impact of economic and non-economic aspects
Regional- and country-level data integrating the demand and supply forces which are influencing the growth of the market
Market value (in USD million) and volume data for each segment and sub-segment
Understanding of the market based on value and volume changes, intra category competition.
Dedicated analyst support for research queries and training
Continuous yearly amendment of the database with significant changes updated based on scenarios
Key Topics Covered:
1. Introduction
2. Research Approach and Methodology
3. Market Segmentation
3.1 By Drug
3.2 By Device
3.3 Geography
4. Market Indicators
5. Company Share Analysis
For more information about this report visit https://www.researchandmarkets.com/r/f3x4je
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900